7 analysts have expressed a variety of opinions on OrthoPediatrics KIDS over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positive shift, the current average has risen by 20.88% from the previous average price target of $33.33.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive OrthoPediatrics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Raises | Buy | $42.00 | $37.00 |
| David Turkaly | JMP Securities | Maintains | Market Outperform | $50.00 | - |
| Mike Matson | Needham | Maintains | Buy | $37.00 | - |
| Samuel Brodovsky | Truist Securities | Raises | Hold | $32.00 | $31.00 |
| Rick Wise | Stifel | Raises | Buy | $34.00 | $32.00 |
| Mike Matson | Needham | Maintains | Buy | $37.00 | - |
| David Turkaly | JMP Securities | Maintains | Market Outperform | $50.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of OrthoPediatrics's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OrthoPediatrics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on OrthoPediatrics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering OrthoPediatrics: A Closer Look
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
OrthoPediatrics's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.36% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: OrthoPediatrics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17.79%, the company may face hurdles in effective cost management.
Return on Equity (ROE): OrthoPediatrics's ROE stands out, surpassing industry averages. With an impressive ROE of -1.78%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, OrthoPediatrics adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
